Research Analysts Offer Predictions for Omnicell, Inc.’s Q4 2024 Earnings (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research lifted their Q4 2024 earnings per share estimates for shares of Omnicell in a research note issued on Friday, July 26th. Zacks Research analyst U. Biswas now forecasts that the company will post earnings of $0.24 per share for the quarter, up from their previous estimate of $0.23. The consensus estimate for Omnicell’s current full-year earnings is $0.25 per share. Zacks Research also issued estimates for Omnicell’s Q1 2025 earnings at $0.13 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.12 EPS and FY2025 earnings at $0.50 EPS.

OMCL has been the topic of several other reports. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Tuesday, July 16th. Benchmark reaffirmed a “buy” rating and set a $38.00 target price on shares of Omnicell in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $42.20.

Omnicell Stock Up 3.7 %

Shares of OMCL opened at $29.39 on Monday. The company has a market capitalization of $1.35 billion, a PE ratio of -63.89, a PEG ratio of 83.15 and a beta of 0.80. Omnicell has a 12 month low of $25.12 and a 12 month high of $66.65. The stock’s 50-day moving average price is $28.62 and its two-hundred day moving average price is $28.99. The company has a current ratio of 2.38, a quick ratio of 2.13 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.17. The firm had revenue of $246.15 million for the quarter, compared to the consensus estimate of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after buying an additional 80,312 shares in the last quarter. Champlain Investment Partners LLC increased its position in Omnicell by 16.0% in the 1st quarter. Champlain Investment Partners LLC now owns 1,753,205 shares of the company’s stock valued at $51,246,000 after buying an additional 241,235 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Omnicell by 2.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,067,516 shares of the company’s stock valued at $40,173,000 after buying an additional 21,798 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Omnicell by 3.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 638,646 shares of the company’s stock valued at $24,032,000 after buying an additional 19,601 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its position in Omnicell by 61.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 599,928 shares of the company’s stock valued at $16,240,000 after buying an additional 228,093 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.